Product Pipeline


RP-G28 is a clinical-stage product candidate that’s mechanism of action is believed to be derived from colonic adaptation (selectively colonizing microbiota) to increase beneficial bacteria in the colon. RP-G28 has completed Phase 2 trials aimed at evaluating its’ safety, efficacy and tolerability. RP-G28 is now in Phase 3 clinical development and is expected to have applicability to multiple types of gastrointestinal (GI) disorders.

Featuring Recent Posts WordPress Widget development by YD